Moderna receives U.S. FDA approval for RSV vaccine mRESVIA(R)
Express Pharma
JUNE 3, 2024
package insert. The most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia and arthralgia. The most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia and arthralgia. per cent (CI 62.9 per cent, 87.8
Let's personalize your content